The global Diagnostic Biomarkers market was valued at USD 45.9 Billion in 2021. It is expected to reach USD 95.1 Billion in 2028, at a CAGR of 12.1% over the forecast period 2022-2028. Biomarkers can be defined as biological processes or chemicals found in bodily fluids like blood. They are then measured in the affected areas. They can indicate healthy or unhealthy bodily functions. Biomarkers can be used for many purposes, including diagnosis of Disease, prediction, treatment response evaluation, and prognosis. Diagnostic biomarkers detect Patent Ductus Arteriosus early in its development (PDA). Predictive markers are used to personalize treatment plans. Prognostic markers can predict survival rates and recurrence patterns. A variety of disorders can be detected using biomarkers in clinical diagnostics. To diagnose renal insufficiency, amylase can diagnose pancreatitis, while troponin levels can be used to diagnose myocardial injury.
Biomarkers can be used to apply clinical trials and analytical epidemiology to understand the dynamics of neurological diseases. Diagnostic biomarkers are useful in expanding our knowledge of the Disease’s underlying pathology and allowing us to classify disease-related risk factors. Biomarkers can be used to provide vital information from the beginning through the end about a disease. A perfect diagnosis requires careful evaluation of biomarkers’ validity concerning each stage. The causes can vary from one person to another and from laboratory to laboratory.
The growth in diagnostic biomarker revenues is expected to increase based on the prevalence of diseases such as cancer and other cardiac problems. The market for diagnostic biomarkers will see significant molecular biology growth and laboratory procedure advancements over the forecast period.
Biomarkers have become easier to diagnose many diseases, including cancers, genetic, heart, and other immunological disorders. Clinical investigators can use biomarkers to help them understand the full spectrum of neurological diseases.
Shortage in Cancer Vaccines
A variety of factors will limit market expansion. Market expansion may be hindered by the inability to provide cancer vaccines for distant areas and the need for special storage and transportation. However, promising growth prospects are possible due to the increasing public awareness of cancer diseases, higher government and private sector investments, and untapped potential within emerging economies.
Diagnostic Biomarkers market scope:
|For Years, Market Size||2016-2030|
Report coverage Market growth drivers, limitations, and opportunities. Porter’s five force analysis, PEST analysis and value chain analysis. Patent analysis. Technology landscape analysis. Company market share analysis. COVID-19 impact analysis.
Market Segmentation :
- Biomarker of Exposure
- Biomarker of Diseases
- Risk Assessment
- Development of Molecular Diagnostic
- Disease Diagnosis
- Drug Discovery and Development
- Drug Formulation
- Forensic Application
- Others (DNA Fingerprinting and Others)
- Sample Preparation
- Assay Development
- Biomarker Validation and Testing
- Other Services
North America Continues to Lead the Diagnostic Biomarkers market.
North America will account for over 34% of global revenue in 2020. This is the largest revenue share. This can be attributed to rising disease burdens and consumer awareness, proactive government efforts, technological advances and improvements in healthcare infrastructure. In 2020, for example, the Canadian government will finance a research project worth USD 78,000 on COVID-19 biomarkers. The study’s goal was to identify biomarkers that could be used to detect COVID-19 severances.
The key players in the Diagnostic Biomarkers Market are BIOMERIEUX, Biocrates Life Sciences Ag, Augurex Life Sciences Corp., Biomedical Corp., ILLUMINA, Ortho Clinical Diagnostics, Myriad Genetics, Target Discovery, Banyan Biomarkers, Inc., Astute Medical, Inc., Axela Inc.
- North America
- The Netherlands
- Czech Republic
- Rest of Europe
- Asia Pacific
- South Korea
- Australia & New Zealand
- Rest of Asia Pacific
- South America
- Rest of South America
- The Middle East & Africa
- Saudi Arabia
- South Africa
- Northern Africa
- Rest of MEA